Lötsch J, Weiss M, Ahne G, Kobal G, Geisslinger G
Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Anesthesiology. 1999 Apr;90(4):1026-38. doi: 10.1097/00000542-199904000-00016.
Morphine is metabolized to two major metabolites, morphine-3-glucuronide and morphine-6-glucuronide (M6G). Under the conditions of long-term oral morphine administration, the accumulation of M6G may contribute to the analgesic effects, but it may also cause respiratory depression.
Five healthy male volunteers (ages 25-34 yr) received 90 mg MST (morphine sulfate 5H2O sustained-released tablet, equivalent to 67.8 mg oral morphine). Multiple plasma and urine samples were taken for as long as 14 and 36 h, respectively. Individual pharmacokinetics after intravenous administration of morphine and M6G were available from a previous investigation. A new model that considers the M6G-plasma profile as a sum of the input from the first-pass metabolism of morphine and the input from systemically available morphine was applied to the plasma concentration versus time curves of M6G. The concentrations of M6G at the effect site after long-term morphine administration were simulated.
The fraction of morphine absorbed from the gut was 82+/-14%. Of this, 42+/-8% passed through the liver, resulting in an oral bioavailability of morphine of 34+/-9%. Of the total amount of M6G, 71+/-7% was formed during the first-pass metabolism, and 29+/-7% was formed by metabolism of systemic morphine. After 36 h, the amounts of M6G and morphine excreted in the urine were 92+/-17% and 9+/-3%, respectively. Simulation of effect-site concentrations of M6G indicated that after multiple oral dosing of morphine in patients with normal liver and renal function, M6G might reach concentrations two times greater than that of morphine.
M6G may contribute to the analgesic and side effects seen with long-term morphine treatment. The current model of morphine and M6G pharmacokinetics after oral administration of morphine may serve as a pharmacokinetic basis for experiments evaluating the analgesic contribution of M6G with long-term oral dosing of morphine.
吗啡可代谢为两种主要代谢产物,即吗啡 - 3 - 葡萄糖醛酸苷和吗啡 - 6 - 葡萄糖醛酸苷(M6G)。在长期口服吗啡的情况下,M6G的蓄积可能有助于镇痛效果,但也可能导致呼吸抑制。
5名健康男性志愿者(年龄25 - 34岁)服用90毫克硫酸吗啡控释片(MST,相当于67.8毫克口服吗啡)。分别在长达14小时和36小时内采集多个血浆和尿液样本。静脉注射吗啡和M6G后的个体药代动力学数据来自先前的一项研究。一种新模型将M6G血浆曲线视为吗啡首过代谢输入和全身可用吗啡输入之和,并应用于M6G的血浆浓度 - 时间曲线。模拟了长期服用吗啡后效应部位的M6G浓度。
吗啡从肠道吸收的比例为82±14%。其中,42±8%经过肝脏,导致吗啡的口服生物利用度为34±9%。在M6G总量中,71±7%在首过代谢过程中形成,29±7%由全身吗啡代谢形成。36小时后,尿液中排出的M6G和吗啡量分别为92±17%和9±3%。M6G效应部位浓度模拟表明,在肝肾功能正常的患者多次口服吗啡后,M6G浓度可能达到吗啡浓度的两倍。
M6G可能促成长期吗啡治疗所见的镇痛和副作用。目前口服吗啡后吗啡和M6G药代动力学模型可为评估长期口服吗啡时M6G镇痛作用的实验提供药代动力学依据。